Tirzepatide attenuates neurotoxicity by suppressing inflammation, apoptosis and restoring neurotrophin expression in an Alzheimer’s disease-like rat model
Authors:
- Mohamed S.M. AttiaMAMohamed S.M. Attia
- Sheikh F. AhmadSASheikh F. Ahmad
- Ahmed NadeemANAhmed Nadeem
- Mushtaq A. AnsariMAMushtaq A. Ansari
- Mohammed A. Al-HamamahMAMohammed A. Al-Hamamah
- Gamaleldin I. HarisaGHGamaleldin I. Harisa
- Saleh A. BakheetSBSaleh A. Bakheet
- Talha Bin EmranTETalha Bin Emran
- Tanveer SinghTSTanveer Singh
- Sabry M. AttiaSASabry M. Attia
- 19 May 2026
- journal article
- letter
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1)
Abstract
Despite numerous milestones in Alzheimer's disease (AD) research, the disease remains incurable, with a high prevalence and significant financial burdens. As a result, researchers are keen to look for new medications that can help manage or prevent the disease. The effects of long-term exposures to tirzepatide, a novel dual GIP/GLP-1 receptor agonist, on neurotoxicity and behavioral changes in the D-galactose/aluminium chloride (D-gal/AlCl3)-induced rats' AD-like pathological model were evaluated. Additionally, we investigated the underlying mechanism for tirzepatide's protective effects against neurotoxicity caused by D-gal/AlCl3. The present findings show that long-term administration of tirzepatide effectively reduced D-gal/AlCl3-induced AD-like neuronal and behavioral deficits and improved rats' learning, spatial memory, and locomotor activity. Tirzepatide restored the aberrant levels of acetylcholine, Aβ1-42, and pTau proteins, major AD hallmarks. Tirzepatide can alleviate behavioral impairments in D-gal/AlCl3-exposed rats by lowering acetylcholinesterase activation and inflammatory markers COX-2, IL-6, and TNF-α levels. This suggests that tirzepatide may alleviate inflammation, leading to restoring the level of acetylcholine and increasing the expression of the neurotrophin BDNF to reduce Aβ-induced neurodegeneration and apoptosis in rats exposed to D-gal/AlCl3. The neuroprotective effect of tirzepatide was also confirmed by lowering the histopathological alterations generated by D-gal/AlCl3 administration, highlighting the possibility of using tirzepatide as a therapeutic candidate to treat AD.Keywords
Funding Information
- King Saud University (ORF-2026-748)
This publication has 51 references indexed in Scilit:
- Crosstalk of TNF-α, IFN-γ, NF-kB, STAT1 and redox signaling in lipopolysaccharide/d-galactosamine/dimethylsulfoxide-induced fulminant hepatic failure in miceSaudi Pharmaceutical Journal, 2023
- Celastrol and thymoquinone alleviate aluminum chloride-induced neurotoxicity: Behavioral psychomotor performance, neurotransmitter level, oxidative-inflammatory markers, and BDNF expression in rat brainBiomedicine & Pharmacotherapy, 2022
- Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registersAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2022
- Apoptotic Pathways and Alzheimer’s Disease: Probing Therapeutic PotentialNeurochemical Research, 2021
- Alzheimer Disease: An Update on Pathobiology and Treatment StrategiesCell, 2019
- d-galactose and aluminium chloride induced rat model with cognitive impairmentsBiomedicine & Pharmacotherapy, 2018
- Role of D-galactose-induced brain aging and its potential used for therapeutic interventionsExperimental Gerontology, 2018
- Acute nicotine treatment prevents rem sleep deprivation‐induced learning and memory impairment in ratHippocampus, 2011
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Maze procedures: the radial-arm and water maze comparedCognitive Brain Research, 1996